JOHNSON & JOHNSON (JNJ) vs Merck & Co., Inc. (MRK)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | JNJ | MRK |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $94.19B | $65.01B |
| Revenue growth (YoY) | ▲ 6.0% | ▲ 1.3% |
| Net income | $26.8B | $18.25B |
| Gross margin | 67.9% | 74.8% |
| Diluted EPS | $11.03 | $7.28 |
| Insider net (6 mo) | −55.1K sh • 7 sells • 0 buys | −101.8K sh • 9 sells • 0 buys |
| Institutional owners | 67 | 67 |
| Institutional value held | $304.18B | $177.99B |
| Next earnings (est.) | Around Jan 20, 2027 | Feb 2, 2027 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About JOHNSON & JOHNSON (JNJ)
Johnson & Johnson is a holding company, incorporated in New Jersey in 1887, whose operating companies research, develop, manufacture and sell a broad range of products in the healthcare field, with a primary focus on human health and well-being. Read more →
About Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a global health care company that delivers innovative health solutions through prescription medicines, including biologic therapies, vaccines and animal health products. Its operations are managed principally on a product basis. Read more →
Source: SEC EDGAR.